In December 2024, the adult sons of Marjorie Tingley received an alarming message from the dementia care unit at Vista Grande Villa, a senior living community in Michigan. Administrators warned that their 85-year-old mother had become a serious safety risk to staff and possibly to herself. According to behavior logs kept by the facility, Tingley had struck, kicked, or elbowed aides on at least ten days that November while they attempted to change her briefs, dress her, bathe her, or help her use the bathroom. Vista Grande requested permission to sedate her.
What followed was a bitter dispute between Tingley's sons and the facility over one of the most controversial practices in long-term care: the use of antipsychotic drugs to calm agitated dementia patients. These medications carry serious risks. The U.S. Food and Drug Administration requires drugmakers to place a boxed warning on their labels stating that the drugs raise the risk of death in older adults with Alzheimer's disease and related dementias.
The conflict reflects a broader national problem. More than five million Medicare beneficiaries carry a dementia diagnosis. Despite a federal campaign spanning fourteen years to curb the use of psychotropic medications in nursing homes, roughly one in four Medicare beneficiaries with dementia is still prescribed antipsychotics or other brain-altering drugs that may be inappropriate. A study published in JAMA found that these medications can trigger delirium, contribute to falls, and lead to hospitalizations.
For families and guardians, the decision is rarely simple. Agitation and aggression are common symptoms of dementia, and caregivers often face a stark choice between allowing distressing behaviors to continue or accepting the risks that come with chemical restraint. Federal regulations discourage the practice, but enforcement varies, and facilities frequently argue that sedation is necessary to protect residents and staff from injury.
Vista Grande Villa's attorneys argued that Tingley's behavior had become unmanageable and that medication was necessary to protect both her and those around her. Her sons, David and his brother, believed the facility was too quick to turn to drugs and worried that sedating their mother would accelerate her decline. They pushed back against the request, setting the stage for a legal and ethical battle that would stretch into the new year.
The case illuminates a dilemma that plays out in thousands of care facilities across the country. Antipsychotics such as haloperidol, risperidone, and quetiapine are not approved to treat dementia-related psychosis or agitation, yet they are widely prescribed off-label. The FDA's warning stems from studies showing that older dementia patients taking these drugs face a significantly higher risk of stroke, pneumonia, and death compared with those given placebos.
The federal government has tried for years to reduce reliance on these medications. The Centers for Medicare & Medicaid Services launched an initiative in 2012 aimed at improving dementia care and cutting unnecessary antipsychotic use in nursing homes. The campaign achieved notable declines in reported use, but progress has stalled in recent years, and some experts question whether facilities are simply documenting diagnoses differently to avoid scrutiny.
Advocates for residents argue that non-drug approaches—such as behavioral therapy, environmental adjustments, and better-trained staff—can often address agitation without the risks of sedation. They point out that antipsychotics are sometimes used for staff convenience rather than genuine medical need. Industry representatives counter that underfunding and inadequate staffing leave facilities with few options when residents become violent.
For the Tingley family, the dispute became deeply personal. David Tingley documented his mother's condition and the facility's requests, eventually sharing his family's experience with journalists. He described the anguish of watching his mother's personality erode while simultaneously fighting to keep her from being medicated into stillness. The family's ordeal underscores how little guidance exists for families caught between a loved one's distress and a system that often defaults to drugs.
Medical experts note that dementia care requires individualized attention. What works for one patient may harm another, and there is no single correct answer when agitation becomes severe. Geriatric psychiatrists emphasize that antipsychotics should be used only as a last resort, at the lowest effective dose, and for the shortest possible time. They also stress the importance of documenting behaviors and trying alternative interventions first.
The Tingley case also raises questions about consent and oversight. In many states, guardians and family members have limited power to refuse recommended medications, particularly when a facility claims a resident poses a danger. Some families have turned to courts or ombudsmen for help, but the process can be slow, expensive, and emotionally draining. Meanwhile, the resident continues to live in the midst of the conflict.
Federal data suggest that the pandemic worsened the situation. Staffing shortages and infection-control challenges left many nursing homes stretched thin, making sedating medications an appealing short-term solution. Although reported antipsychotic use declined modestly during the pandemic, researchers caution that the numbers may not capture the full picture, since some prescriptions are recorded for conditions like schizophrenia or bipolar disorder rather than dementia.
As the American population ages, the number of people living with dementia is expected to grow substantially, intensifying the pressure on long-term care facilities. Without major investments in staffing, training, and alternative therapies, experts warn that the default use of antipsychotics will continue. The Tingley family's fight is unlikely to be the last of its kind, but it offers a window into the difficult choices that lie ahead for millions of families.
For now, the question at the heart of the case remains unresolved: When a person with dementia becomes agitated and dangerous, who decides whether the risks of sedation outweigh the risks of doing nothing? The answer, as the Tingley family discovered, is rarely clear, and the consequences can last far longer than the dispute itself.
(0)